BGB-43395-101 (CDK-4) - A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395
Clinical Trial Grant
Awarded By
BeiGene USA, Inc.
Start Date
January 26, 2024
End Date
January 21, 2029
Awarded By
BeiGene USA, Inc.
Start Date
January 26, 2024
End Date
January 21, 2029